Scarica l'app Stockscreener
2.00
1.48%
-0.03
Dopo l'orario di chiusura:
2.05
0.05
+2.50%
Precedente Chiudi:
$2.03
Aprire:
$2.05
Volume 24 ore:
56,283
Relative Volume:
0.37
Capitalizzazione di mercato:
$25.65M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.41%
1M Prestazione:
-20.00%
6M Prestazione:
-63.30%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.93
$2.09
Intervallo di 1 settimana:
$1.91
$2.23
Portata 52W:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Nome
Onkure Therapeutics Inc
Settore
Industria
Telefono
(720) 307-2892
Indirizzo
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Confronta OKUR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.00 | 27.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-30 | Iniziato | Evercore ISI | Outperform |
| 2024-12-05 | Iniziato | Leerink Partners | Outperform |
| 2024-10-10 | Iniziato | Oppenheimer | Outperform |
| 2023-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | Downgrade | Jefferies | Buy → Hold |
| 2023-12-15 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-12-14 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | Iniziato | William Blair | Outperform |
| 2023-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-03 | Iniziato | BofA Securities | Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-27 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-22 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-04 | Iniziato | Jefferies | Buy |
| 2021-05-04 | Iniziato | Piper Sandler | Overweight |
| 2021-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Onkure Therapeutics Inc Borsa (OKUR) Ultime notizie
Onkure Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - GlobeNewswire
Will OnKure Therapeutics Inc. stock recover after recent dropStock Holding Strategy Long-Term Summary Sheet - Newser
How sentiment analysis helps forecast OnKure Therapeutics Inc.Free Access to Real-Time Trade Insights - Newser
How to monitor OnKure Therapeutics Inc. with trend dashboardsLow Risk High Confidence Watchlist Builder - Newser
Applying big data sentiment scoring on OnKure Therapeutics Inc.Daily Investment Ideas with Market Insight - Newser
Price momentum metrics for OnKure Therapeutics Inc. explainedLong-Term Safety Investment Analysis Report - Newser
OnKure Therapeutics Inc. stock outlook for YEARReal Time Growth Signal with Smart Setup - Newser
What makes OnKure Therapeutics Inc. stock price move sharplyShort-Term AI-Based Stock Price Forecast - Newser
OnKure Therapeutics (OKUR) to Release Earnings on Tuesday - Defense World
Is OnKure Therapeutics Inc. Stock a Good Fit for Conservative InvestorsDay Trading Setup Forecast with Trend Model - Newser
OnKure Therapeutics Inc. stock trend forecastQuarterly Investment Outlook and Key Summary - Newser
Using data models to predict OnKure Therapeutics Inc. stock movementFree Buy Low Sell High Stock Watch - Newser
Using data filters to optimize entry into OnKure Therapeutics Inc.Entry Zone Watchlist With Momentum Focus - Newser
Why OnKure Therapeutics Inc. stock attracts strong analyst attentionFree Scalable Portfolio Growth Suggestions - Newser
How many analysts rate OnKure Therapeutics Inc. as a “Buy”Get ahead with breakthrough trading ideas - Jammu Links News
What is OnKure Therapeutics Inc. company’s growth strategyFree Buy/Sell Signal Notifications - Jammu Links News
What drives OnKure Therapeutics Inc. stock pricePhenomenal capital gains - Jammu Links News
How strong is OnKure Therapeutics Inc. company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is the risk reward ratio of investing in OnKure Therapeutics Inc. stockUnlock powerful trading signals for profits - Jammu Links News
When is OnKure Therapeutics Inc. stock expected to show significant growthHigh-profit stock alerts - Jammu Links News
Is OnKure Therapeutics Inc. a good long term investmentInvest smarter with daily stock recommendations - Jammu Links News
What are the technical indicators suggesting about OnKure Therapeutics Inc.Capitalize on market shifts before others do - Jammu Links News
How does OnKure Therapeutics Inc. generate profit in a changing economyCapitalize on emerging market sectors - Jammu Links News
Why is OnKure Therapeutics Inc. stock attracting strong analyst attentionAchieve impressive returns with smart timing - Jammu Links News
How to use a screener to detect OnKure Therapeutics Inc. breakoutsIn-Depth Stock Trading Volume Analysis - Newser
Onkure Therapeutics Inc Azioni (OKUR) Dati Finanziari
Non sono disponibili dati finanziari per Onkure Therapeutics Inc (OKUR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Onkure Therapeutics Inc Azioni (OKUR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):